Genedrive (GB:GDR) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genedrive PLC has reported significant advances in its pharmacogenetic testing products, with revenues reaching £0.5 million and a successful £6 million equity fundraise. The company received positive endorsements from NICE and the FDA, and its products are now being used in the UK and overseas. With a strong cash position and ongoing market expansion efforts, Genedrive is poised for growth in 2025.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.